TIDES China Digital Week: Addressing the Challenges in Developing a Control Strategy for Therapeutic Oligonucleotides

Addressing the Challenges in Developing a Control Strategy for Therapeutic Oligonucleotides: Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharma

Oligonucleotides require a control strategy which presents significant analytical challenges. We will discuss how to address accurate and reproducible impurity control and the best approaches for reproducible impurity separation and quantitation, as well as product purity. We will also cover the determination of the consistency of the diastereomeric ratio of phosphorothioated oligonucleotides.

Mike Webb, PhD, was the VP of Development Chemistry and Analysis for GSK in the UK and was heavily involved in developing GSK’s oligonucleotide pipeline. Since leaving GSK in 2016 he has been consulting with Big Pharma and Biotechnology companies in the development, analysis and manufacture of therapeutic oligonucleotides from pre-clinical to marketing submission.

TIDES China Digital Week:

1. "Take the Wheel and Drive Your Oligo Synthesis Where You Want," with Carina Strandh
2. "Manufacturing Aspects of a Phase 1 Oligonucleotide IND," with Kathryn L. Ackley
3. "Your ÄKTA Oligosynt™ System: It’s More Than a Machine," with Peter Guterstam

Click the links above to watch the webcasts